Ability Pharma is a private clinical-stage biopharmaceutical company based in Barcelona, Spain. The company is developing a first-in-class autophagy treatment for solid tumors. Its lead asset, ABTL0812, is in Phase 2b study for first-line metastatic pancreatic cancer.
Pancreatic cancer
CTI LSF III
Lead
Director & Observer
January 24, 2024
Active
Series A
Ability Pharma has a first-in-class autophagy driven treatment for metastatic pancreatic cancer, one of the deadliest cancers, and its interim blinded Phase 2b data suggested a significant improvement over the current standard of care
March 11, 2024
September 9, 2024
